Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

melagatran

Known as: N-((R)-(((2S)-2-((-p-amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
OBJECTIVE Inflammatory mechanisms are involved in atherosclerotic plaque rupture and subsequent thrombin formation. Thrombin not… Expand
  • figure 1
  • figure 3
  • table 2
  • figure 2
  • table 3
Is this relevant?
2004
2004
The objectives were to investigate whether activation of the extrinsic coagulation cascade by recombinant factor VIIa (rFVIIa… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
We evaluated whether a postoperative regimen with melagatran followed by oral ximelagatran, two new direct thrombin inhibitors… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Ximelagatran and its subcutaneous (s.c.) form melagatran are novel direct thrombin inhibitors for the prevention and… Expand
Is this relevant?
2003
2003
ObjectiveTo determine the influence of ethnic origin on the pharmacokinetic and pharmacodynamic properties of melagatran after… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
A thrombotic/inflammatory reaction is elicited when isolated islets of Langerhans come in contact with ABO-compatible blood. The… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Heparins substantially reduce the risk of thromboembolic complications after total hip or knee replacement. However… Expand
Is this relevant?
2002
2002
The novel, oral direct thrombin inhibitor, ximelagatran (formerly H 376/95), represents an advance in antithrombotic therapy… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
UNLABELLED Suboptimal gastrointestinal absorption is a problem for many direct thrombin inhibitors. The studies presented herein… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Melagatran, a new, competitive and rapid inhibitor of thrombin with a molecular mass of 429 Da is described. Melagatran is well… Expand
Is this relevant?